Lebrikizumab demonstrated significant efficacy in improving skin clearance, itch, and pigmentary changes in a phase 3b trial involving adult and adolescent patients with skin of color suffering from moderate-to-severe atopic dermatitis. Over 24 weeks, 78% of participants achieved a 75% improvement on the Eczema Area and Severity Index (EASI 75), and 54% obtained clear to nearly clear skin. Safety assessments showed a manageable profile with minor adverse events and no serious incidents. The study indicates the drug's potential but calls for longer studies to validate these results and explore long-term implications.

Source: American Journal of Clinical Dermatology